FDA Approves Crispr Sickle Cell

6.5

520d

The FDA has approved two gene therapies for sickle cell disease, marking a major breakthrough in the treatment of the condition. The therapies utilize CRISPR technology and have the potential to cure the disease, although there are concerns about side effects and accessibility for Black patients.

Generated by A.I.

Main Left Right

The U.S. Food and Drug Administration (FDA) has approved two gene therapies for the treatment of sickle cell disease, marking a significant breakthrough in the field of genetic medicine. The first therapy, called CASGEVY (exagamglogene autotemcel), was developed by Vertex Pharmaceuticals and CRISPR Therapeutics. It is a one-time treatment that uses CRISPR gene-editing technology to modify the patient's own stem cells and potentially cure sickle cell disease.

The second therapy, developed by bluebird bio, is called betibeglogene autotemcel. It is also a one-time treatment that involves modifying the patient's own stem cells to produce a form of hemoglobin that is less prone to sickling.

Sickle cell disease is a genetic disorder that affects the shape and function of red blood cells. It can cause a range of symptoms, including pain, fatigue, organ damage, and an increased risk of infections. Currently, the disease is managed with blood transfusions, medication, and other supportive treatments, but there is no cure.

The FDA's approval of these gene therapies has sparked hope among patients and healthcare professionals that a cure for sickle cell disease may finally be within reach. However, there are also concerns about the high cost of the therapies and their accessibility for all patients, particularly those from marginalized communities.

The approval of these gene therapies represents a significant milestone in the field of genetic medicine and highlights the growing importance of gene editing technologies, such as CRISPR, in the treatment of genetic diseases. It is hoped that these therapies will provide a new treatment option for patients with sickle cell disease and pave the way for further advancements in gene therapy.

Overall, the approval of these gene therapies for sickle cell disease has the potential to revolutionize the treatment of the condition and provide hope for the thousands of individuals affected by it.

Q&A (Auto-generated by AI)

Current Stats

Data

Virality Score 6.5

Change in Rank +4

Thread Age 520 days

Number of Articles 66

Political Leaning

Left 32.1%

Center 50.0%

Right 17.9%

Regional Coverage

US 77.4%

Non-US 22.6%

Recent Coverage

The FDA issued its first approval of a CRISPR gene-editing therapy.

The Verge - 520 days ago - The US Food and Drug Administration announced the approval of two gene-based therapies for sickle cell disease, one of which uses the genome editing technology CRISPR. It’s a big milestone, but access to the therapies for now will still be very limited and expensive, the New York Times explains.

1st gene therapies for sickle cell cleared by FDA, including CRISPR treatment

Live Science - 520 days ago - The FDA approved two new therapies for sickle-cell disease, including the world's first-ever approved CRISPR therapy.

US approves sickle cell breakthrough with gene editing therapy

Medical Xpress - 520 days ago - The United States on Friday approved a breakthrough medicine that uses revolutionary gene editing tool CRISPR to treat the debilitating blood disorder sickle cell disease.

First CRISPR Sickle Cell Patient ‘Reborn’: FDA Approves Treatment

Forbes - 520 days ago - The FDA's approval of Casgevy, which uses the Nobel Prize-winning gene-editing therapy to treat patients with sicke cell disease, opens the door to many other therapies.

Two new cutting-edge sickle cell treatments approved by FDA despite side effects

New York Post - 520 days ago - The U.S. Food and Drug Administration (FDA) on Friday approved a pair of gene therapies for sickle cell disease, including the first treatment based on the breakthrough CRISPR gene editing technolo…

Q&A: How serious is FDA warning about revolutionary blood-cancer treatment?

Medical Xpress - 520 days ago - The Food and Drug Administration announced last week that it's investigating reports of secondary cancers in patients who received CAR T-cell therapy, one of a suite of immunotherapies that have revolutionized cancer care over the past decade. The treatment reprograms a patient's T cells, a key part of the immune system, to recognize and attack cancer cells.

US Approves Two Gene Therapies for Sickle Cell Disease

VOA News - 520 days ago - Makers of both the therapies have pitched them as one-time treatments, but data on how long their effect lasts is limited

Astellas Pharma US, Inc. Announces FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis

MarketScreener - 520 days ago - Astellas Pharma US Inc. announced that the U.S. Food and Drug Administration has approved CRESEMBA® , an azole antifungal drug, for the treatment of invasive aspergillosis and invasive mucormycosis...

FDA Approves First CRISPR Treatment in U.S.

Time - 520 days ago - Two new therapies—one which uses the gene-editing technology—treat sickle cell anemia.

US FDA to approve $2 million potential cure for sickle cell patients

Nairametrics - 520 days ago - The U.S. Food and Drug Administration is set to approve Exa-cel, a potential cure for sickle cell patients, with an

Boston companies make history with FDA approval of CRSPR-based gene therapy for Sickle Cell Disease

WCVB - 520 days ago - Casgevy, made by two Boston-based pharmaceutical companies, is the first gene therapy based on a technology sometimes called "genetic scissors."

FDA Approves First Crispr Treatment That Might Cure Sickle Cell

Forbes - 520 days ago - The Food and Drug Administration approved a new gene editing therapy for sickle cell disease, its first green light for a Crispr treatment.

FDA approves two sickle cell therapies, including first CRISPR medicine

The Washington Post - 520 days ago - The therapies offer hope for a long-overlooked genetic illness that can cause excruciating pain and cut decades off people’s lives.

FDA approves 2 gene therapies for sickle cell disease

Global News - 520 days ago - The U.S. FDA on Friday approved two gene therapies for sickle cell disease from Vertex Pharmaceuticals and CRISPR Therapeutics, as well as from bluebird bio.

F.D.A. Approves Sickle Cell Treatments, Including One That Uses CRISPR

The New York Times - 520 days ago - People with the genetic disease have new opportunities to eliminate their symptoms, but the treatments come with obstacles that limit their reach.

FDA approves world's first CRISPR gene-editing drug for sickle cell disease

Washington Examiner - 520 days ago - The Food and Drug Administration has approved the world's first medicine employing CRISPR gene-editing technology to treat sickle cell disease, giving thousands new hope to treat the painful disease.

U.S. FDA approves two gene therapies for sickle cell disease

The Globe and Mail - 520 days ago - Sickle cell disease is a painful, inherited blood disorder that can be debilitating and lead to premature death

FDA Approves Two Sickle Cell Disease Gene Therapies

Newsmax - 520 days ago - The U.S. Food and Drug Administration (FDA) on Friday approved a pair of gene therapies for sickle cell disease, including the first treatment based on the breakthrough CRISPR gene editing technology.The agency approved Lyfgenia from bluebird bio, and a separate treatment...

FDA approves first gene-editing treatment for human illness

NPR - 520 days ago - The Food and Drug Administration approved two genetic treatments for sickle cell disease, including one that uses gene-editing. The approvals offer hope for patients and signal a new medical era.

FDA approves gene therapy for sickle cell disease: 'One incredible journey of success.'

USA Today - 520 days ago - The FDA approves the first of two gene therapies this month to treat sickle cell disease. Though expensive and difficult, it promises a better life.

FDA Expected To Approve First Crispr Gene-Editing Treatment, Bringing Hope To Thousands With Sickle Cell Disease - The Seattle Medium

The Seattle Medium - 520 days ago - One of an estimated 100,000 people in the US with sickle cell disease, Johnny Lubin was one of the first in the world to try a new kind of medicine: one that uses a gene-editing tool called CRISPR to offer a potential cure.